Cancer Centers of Southwest Oklahoma

Lawton, Oklahoma 73505

0 studies enrolling now · 13 studies all time

What they study most

Advanced Breast Cancer, Advanced Prostate Cancer, Bladder Cancer, Breast Cancer, Breast Tumor, Cancer of the Breast, Colorectal Cancer, DCIS, Diffuse Large B-Cell Lymphoma, Ductal Carcinoma in Situ, Esophageal Cancer, Estrogen Receptor- Negative Breast Cancer

Studies at this site

• MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles — Recruiting now
• Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS — Running, not enrolling
• A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer — Running, not enrolling
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors — Completed
• A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes — Stopped early
• Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma — Completed
• Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer — Completed
• A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer — Completed
• Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) — Completed
• Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy — Completed
• Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer — Completed
• Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma — Completed
• Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC — Completed